- Zacks•7 hours ago
Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
- Investor's Business Daily•8 hours ago
Gilead and GSK will have a tough time divorcing HIV patients from their traditional three-pill regimens, Leerink said Wednesday,
- Barrons.com•12 hours ago
The Conference on Retroviruses and Opportunistic Infections (CROI) Annual Meeting took place last week, and while this meeting is one of the most important for HIV treatment data, it's closed to investors and non-clinicians. As such, Leerink's Geoffrey Porges and Bradley Canino hosted a call with two specialists in HIV treatment, to discuss their impressions of the meeting. Specifically, they discussed the specialists' reactions to Gilead's (GILD) bictegravir, GlaxoSmithKline's (GSK) dolutegravir two-drug combinations, and Merck's (MRK) doravirine, as well as Gilead's tenofovir alafenamide fumarate (TAF) adoption in the US and Europe.
GSK : Summary for GlaxoSmithKline PLC Common Stoc - Yahoo Finance
GlaxoSmithKline plc (GSK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||40.94 - 41.24|
|52 Week Range||37.20 - 45.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||88.43|
|Dividend & Yield||2.00 (4.85%)|
|1y Target Est||N/A|